Drugs / clofutriben
clofutriben
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07227922 | Nov 2025 → Apr 2026 overdue | — | Sparrow Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07226635 | Oct → Dec 2025 | — | Sparrow Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06281236 | Feb 2022 → Mar 2025 | polymyalgia rheumatica | Sparrow Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT05409027 | Jul 2021 → Mar 2022 | obesity disorder, type 2 diabetes mellitus | Sparrow Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02194491 | Apr 2014 → May 2016 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07296484 | Nov 2025 → Dec 2027 expected | Cushing syndrome, type 2 diabetes mellitus | Sparrow Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT05436639 | Jul 2023 → Dec 2024 | ACTH-independent adrenal Cushing syndrome, somatic | Sparrow Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05307328 | Sep 2022 → Aug 2025 | ACTH-dependent Cushing syndrome, ectopic ACTH secretion syndrome | Sparrow Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05436652 | Jul 2022 → Apr 2025 | polymyalgia rheumatica | Sparrow Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02372578 | May 2015 → May 2016 | diabetic polyneuropathy | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clofutriben | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226635 ↗ |
| Known as | AS-2473662 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314513 ↗ |
| Known as | ASP3662 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02372578 ↗ |
| Known as | Clofutribene | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314513 ↗ |
| Known as | HDD-1697 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314513 ↗ |
| Known as | SPI-62 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05436639 ↗ |
| Action | Inhibit | “11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor” NCT05307328 ↗ |
| Modality | Small molecule | — CHEMBL5314513 ↗ |
| Route | Oral | “single oral dose administration of ASP3662” NCT02194491 ↗ |